Growth-Related Disorders
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Communication Preferences
Sign Out
Sign In | Create Account
  • Growth-Related Disorders Home
    • Products
      Treatment & Diagnostic Test
    • Professional Resources
      Product Resources Library Contact Your Representative
    • Disease Education
      Clinical Education Resources Pediatric Growth-Related Disorders (Basics) Adult Growth Hormone Deficiency
    • Treatment Guidelines
      PES & AACE Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Resources Advocacy & Support Groups
    • Access & Affordability
      Insurance Support & Prescription Savings
  • Sign In
    Create Account
    • Account Settings
    • Communication Preferences
    • Sign Out
    Medical Information
    Non-US Health Care Professionals
Macrilen™ (macimorelin) 60 mg for oral solution logo
Important Safety Information
Prescribing Information
  • About Macrilen™
  • Efficacy & Safety
  • Dosing & Administration
  • Coverage & Savings
  • How to Order
  • Resources
Macrilen™ (macimorelin) 60 mg for oral solution logo

For the diagnosis of adult growth hormone deficiency.

Prescribing Information
Important Safety Information

Diagnosis made simpler. Decisions made clear.

Macrilen™ (macimorelin) for oral solution is the first and only FDA-approved Adult Growth Hormone Deficiency (AGHD) oral diagnostic test available for in-office use.1

About Macrilen™
20-something white male with a happy expression is leaning against a giant glass of reconstituted Macrilen™ (macimorelin) 60 mg oral solution.
Diagnosis made simpler. Decisions made clear.

Macrilen™ (macimorelin) for oral solution is the first and only FDA-approved Adult Growth Hormone Deficiency (AGHD) oral diagnostic test available for in-office use.1

About Macrilen™

Studied against the ITT

Macrilen™ (macimorelin) 60 mg icon of pages representing data and information found during the clinical trial process

Macrilen™ was studied in 140 adults in a head-to-head trial vs. the insulin intolerance test (ITT).1,a,b

View trial results

In-office administration

Macrilen™ (macimorelin) 60 mg icon illustrating a patient drinking a prepared oral solution

Prepare, dose, administer, and send for results.

See the steps

Multiple ways to order

Macrilen™ (macimorelin) 60 mg icon of an order form page representing the ordering process

You can contact a specialty pharmacy directly or use our request form, which also enables us to verify patient benefits and eligibility for co-pay assistance.

Explore options
View trial results
See the steps
Explore options

aThe diagnostic efficacy of the Macrilen™ test was established in a randomized, open-label, single-dose, cross-over study. The objective of the study was to compare the level of agreement between Macrilen™ test results and ITT results in adult patients with different pre-test probability of growth hormone deficiency and healthy control subjects. Each participant was to undergo the two diagnostic tests and serve as his or her own control. One hundred and fifty-seven subjects underwent at least one of the two tests in this study. Data on both tests were available for 140 subjects. One out of 154 Macrilen™ tests performed failed due to a technical error and 27 out of 157 ITTs performed failed because induction of severe hypoglycemia could not be achieved.1
b
Studied in adult subjects with different pretest probabilities of GH deficiency (GHD) and in healthy control subjects.1

Macrilen™ (macimorelin) 60 mg icon representing a patient hand receiving money from the co-pay savings program

Eligible patients may pay as little as $75 with the Macrilen™ Co-pay Savings Program.c,d

Learn about co-pay

Eligible patients may pay as little as $75 with the Macrilen™ Co-pay Savings Program.c,d

Learn about co-pay

cWith an annual co-pay assistance of up to $4425.
dThis is a one-time use offer. Enrollment in the co-pay program is subject to eligibility criteria and terms and conditions, and the enrollment timeframe is based on calendar year. Patient is not eligible if he/she participates in or seeks reimbursement or submits a claim for reimbursement to any Government Program. Patient must be enrolled in a commercial insurance plan. Coverage is limited to co-pay or co-insurance for Macrilen™ product only and does not include deductible amounts or other office visits, procedures, or administration costs. Novo Nordisk has the right to charge, alter, or revoke eligibility criteria and terms and conditions at any time.

Have you created your novoMEDLINK™ account?

Sign up now to receive news about growth-related disorders and product updates from Novo Nordisk.

Create your account

Selected Important Safety Information for Macrilen™

Warnings and Precautions

  • QT Prolongation: Macrilen™ causes an increase of about 11 msec in the corrected QT (QTc) interval. QT prolongation can lead to development of torsade de pointes-type ventricular tachycardia with the risk increasing as the degree of prolongation increases. The concomitant use of Macrilen™ with drugs that are known to prolong the QT interval should be avoided

Indication and Limitation of Use

Macrilen™ (macimorelin) 60 mg for oral solution is indicated for the diagnosis of adult growth hormone deficiency (AGHD).

  • The safety and diagnostic performance of Macrilen™ have not been established for subjects with a body mass index (BMI) >40 kg/m2

Important Safety Information

Warnings and Precautions

  • QT Prolongation: Macrilen™ causes an increase of about 11 msec in the corrected QT (QTc) interval. QT prolongation can lead to development of torsade de pointes-type ventricular tachycardia with the risk increasing as the degree of prolongation increases. The concomitant use of Macrilen™ with drugs that are known to prolong the QT interval should be avoided
  • Potential for False Positive Test Results with Use of Strong CYP3A4 Inducers: Concomitant use of strong CYP3A4 inducers with Macrilen™ can decrease macimorelin plasma levels significantly and thereby lead to a false positive result. Strong CYP3A4 inducers should be discontinued and enough time should be given to allow washout of CYP3A4 inducers prior to test administration
  • Potential for False Negative Test Results in Recent Onset Hypothalamic Disease: Adult growth hormone (GH) deficiency caused by a hypothalamic lesion may not be detected early in the disease process. Macimorelin acts downstream from the hypothalamus and macimorelin stimulated release of stored GH reserves from the anterior pituitary could produce a false negative result early when the lesion involves the hypothalamus. Repeat testing may be warranted in this situation 

Adverse Reactions

  • The most common adverse reactions are dysgeusia, dizziness, headache, fatigue, nausea, hunger, diarrhea, upper respiratory tract infection, feeling hot, hyperhidrosis, nasopharyngitis, and sinus bradycardia

Please click here for Macrilen™ Prescribing Information.

 

References:

  1. Macrilen [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; 2021.
Growth-Related Disorders
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
  • Growth-Related Disorders Home
  • Product Information
    Products
    • Treatment & Diagnostic Test
    Professional Resources
    • Product Resources Library
      Contact Your Representative
  • Professional Education
    Disease Education
    • Clinical Education Resources
      Pediatric Growth-Related Disorders (Basics)
      Adult Growth Hormone Deficiency
    Treatment Guidelines
    • PES & AACE Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Resources
      Advocacy & Support Groups
    Access & Affordability
    • Insurance Support & Prescription Savings

Macrilen™ is a trademark of Aeterna Zentaris GmbH, licensed exclusively in the U.S. and Canada to Novo Nordisk Biopharm Limited.
novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.

Legal Notice | Privacy Policy | Cookie Policy | Contact Us |
novonordisk-us.com    
© 2021 Novo Nordisk All rights reserved.  US21MAC00004 October 2021

Quick links

Treatment & diagnostic test

Insurance support & patient savings

Pediatric disorders overview

Clinical education for your patients